Cells from patients with MDS-derived AML display heterogeneous proliferative responses to transforming growth factor beta (TGF␤). We analyzed growth inhibition and SMAD2 phosphorylation by TGF␤ in CD34 + cells from nine patients, as compared to normal controls. While TGF␤ consistently inhibited thymidine incorporation of normal cells (41% of control, P Ͻ 0.05), cells from patients with AML were growth-inhibited in only four of seven cases (40%), whereas TGF␤ stimulated thymidine incorporation in the three other samples (166%). Remarkably, TPO reverted the stimulatory effect of TGF␤ to profound growth inhibition. Upon exposure to TGF␤, SMAD2 protein was phosphorylated in normal CD34
Introduction
Transforming growth factor beta (TGF␤) is a potent growth inhibitor of hematopoietic stem and progenitor cells, 1,2 more mature cells being less responsive, [3] [4] [5] and TGF␤ controls the differentiation of hematopoietic cells. [6] [7] [8] TGF␤ interferes with other growth factors which stimulate the proliferation of CD34
+ hematopoietic progenitor cells such as thrombopoietin (TPO), 9 and it antagonizes TPO-induced growth of megakaryoblastic M-07e cells. 10 TGF␤ signaling occurs through two transmembrane receptors which upon ligand binding phosphorylate intracellular Sma-and Mad-related (SMAD) proteins.
11 SMAD2 and SMAD3 are TGF␤ receptor-associated signaling molecules, and activated SMAD2 and SMAD3 proteins form heterodimers with SMAD4 which then translocate to the nucleus and initiate transcription of TGF␤-responsive genes.
11 SMAD2 is known to mediate TGF␤-induced growth arrest. 11 Alterations of SMAD2, such as mutations of the gene 12 or overexpression of messenger RNA 13 of gastrointestinal cancers, and targeted disruption of SMAD2 in mice leads to severe embryonic defects.
14 Cells from patients with acute myeloid leukemia (AML) display heterogeneous responses to TGF␤. [15] [16] [17] Most authors have found TGF␤ to inhibit the proliferation of blasts from patients with AML. However, when coadministered with growth-stimulatory factors, TGF␤ was able to stimulate blast cell proliferation. 16, 18 Moreover, clonogenic cells from patients with AML evolving from myelodysplastic syndromes (MDS) have been demonstrated to be resistant to TGF␤-induced growth inhibition. 17 Possible causes for this include decreased receptor expression and abnormalities in the TGF␤ signal transduction pathway. Apart from growth-inhibitory molecules such as TGF␤, cells from patients with MDS and AML have been demonstrated to display heterogeneous responses to growth-stimulatory cytokines such as TPO, 19, 20 which were attributed to heterogeneous c-mpl receptor expression, 20 as well as defects of TPO-associated signal transduction. 21 While these data suggest that multiple signaling defects may be responsible for the growth of leukemic cells in AML, the underlying molecular mechanisms are still incompletely understood.
Since SMAD2 mutations have not been found in leukemias 22 and since TGF␤-induced phosphorylation of SMAD2 has not been studied in leukemia, it was asked whether defective SMAD2 phosphorylation was associated with an altered proliferative response to TGF␤ in MDS-derived AML. Therefore, TGF␤-induced growth inhibition in CD34 + hematopoietic progenitor cells from patients with AML after MDS was investigated. It was analyzed whether TGF␤-associated signaling was defective in CD34 + cells from these patients with AML as compared to CD34 + cells from healthy donors and whether the activation of SMAD2 was associated with TGF␤-mediated growth inhibition. Moreover, it was studied whether TGF␤-mediated effects were modified by selective inhibitors of TPOinduced signaling molecules such as Janus-activated kinase and signal transducers and activators of transcription (JAK-STAT) and mitogen-activated protein kinase (MAPK) proteins.
Materials and methods

Patients and bone marrow samples
Heparinized bone marrow samples were obtained by aspiration from the posterior iliac crest from patients with AML after MDS (n = 9) undergoing diagnostic bone marrow aspiration, or from healthy donors (n = 4) ( Table 1) . Patients had not received chemotherapy except for one patient with AML after MDS who had failed induction chemotherapy (case AML8). Patients AML8 and AML9 were evaluated only in Western blotting experiments. In addition, G-CSF mobilized peripheral blood CD34
+ cells from healthy donors (n = 3) were used for Western blotting experiments. All cells were obtained 
Purification of CD34 + cells from healthy controls and patients with AML after MDS
CD34
+ isolation was performed as described earlier. 19 Briefly, Ficoll-separated nonadherent mononuclear cells were subjected to immunomagnetic selection of CD34 + cells using MACS columns (Miltenyi Biotec, Bergisch Gladbach, Germany). The purity of the positively selected CD34 + cells as evaluated by flow cytometry (FACScan; Becton Dickinson, Heidelberg, Germany) was 91 ± 5% (mean ± s.d.). Following isolation, CD34 + cells were either cryopreserved in 10%DMSO/10%FCS or used immediately. Viability of cells used for culture was 90 ± 8% irrespective of whether they had been cryopreserved or not.
Cell culture HEL 92.1.7 (HEL) cells obtained from the American Type Culture Collection (Manassas, VA, USA) and M-07e cells obtained from the German Collection of Microorganisms and Cell Cultures (Braunschweig, Germany) were propagated in RPMI 1640 medium supplemented with 10% (vol/vol) fetal calf serum (FCS) (HyClone, Logan, UT, USA), 2 mM L-glutamine, 10 U/ml penicillin and streptomycin (all from Gibco, Eggenstein, Germany). CD34
+ cells were seeded in 12-well plates at 1 × 10 5 /ml in Iscove's modified Dulbecco's medium (IMDM) (Biochrom, Berlin, Germany), supplemented with 10% FCS, 2 mM L-glutamine, 10 U/ml penicillin and streptomycin. CD34 + cells were cultured at 37°C and 5% CO 2 in a fully humidified atmosphere for 2 to 4 days in the absence of exogenous cytokines, or in the presence of either 100 ng/ml pegylated recombinant human megakaryocyte growth and development factor (MGDF) (generously provided by Amgen, Thousand Oaks, CA, USA), or 100 ng/ml transforming growth factor beta-1 (TGF␤) (Cell Concepts, Umkirch, Germany), or both cytokines. In some experiments, 10 ng/ml human interleukin-3 (IL-3) (Cell Concepts, Umkirch, Germany) was Leukemia used as indicated. For inhibition of JAK2 and MAPK, cells were preincubated with 100 M AG490 or 20 M PD098059, respectively, for 4 h (both reagents from Calbiochem, Schwalbach, Germany). After 2 and 4 days an aliquot of cells was removed from the cultures for assessment of viability using trypan blue exclusion.
Proliferation assay
Cells to be analyzed for proliferation in 3 H-thymidine incorporation were seeded in triplicates at 1 × 10 4 cells per well in 96-well microtiter plates (Greiner, Frickenhausen, Germany) and cultured at 37°C and 5% CO 2 in the decribed medium in a final volume of 100 l. Cells were incubated either without exogenous cytokines, or with 100 ng/ml TPO, 100 ng/ml TGF␤, or both. After 24 h, 37 kBq per well (methyl) 3 H-thymidine (1.92 TBq/mmol) (Amersham Life Science, Little Chalfont, UK) was added in a volume of 25 l of IMDM, and cells were incubated overnight at 37°C for approximately 12 h. Samples were harvested and analyzed in a Tri-Carb 1500 Liquid Scintillation Analyzer (Packard Instrument, Groningen, The Netherlands) as described previously, 23 and results are expressed as mean counts per minute (cpm) of triplicate determinations.
Preparation of CD34 + cell lysates and Western blotting
Western blotting was essentially performed as described previously. 24 Briefly, 5 × 10 6 CD34 + cells were serum-starved for 1 h at 37°C in IMDM medium lacking FCS in the presence or absence of 100 ng/ml TGF␤ before 10 min of exposure to either no cytokine or 100 ng/ml TPO. Cells were lysed in 20 mM Tris-HCl, pH 7.5, 137 mM NaCl, 1% (vol/vol) NP-40, 10 mM ethylendiamine tetraacetic acid, 10% (vol/vol) glycerol with the addition of 0.2 mM Na 3 VO 4 , 1 mM NaF, 1 mM pepstatin, 1 mM phenylmethylsulfonyl fluoride, 1 mM 1,10-phenanthroline, 5 mM leupeptin, and 100 U/ml aprotinin (all from Sigma, Munich, Germany) and centrifuged. Protein concentration was determined in the supernatant by a modified Lowry DC protein assay (BioRad, Hercules, CA, USA), and the amount of protein was adjusted to be equivalent in each sample. In addition, membranes were stained by Ponceau Red to verify equal loading and transfer of the proteins. Twenty to 40 g of protein were denatured in 2× buffer including ␤-mercaptoethanol and separated by sodium dodecyl-polyacrylamide gel electrophoresis (SDS-PAGE) (10% PA), and proteins were blotted on to nitrocellulose membranes (BioRad). Blots were blocked with 5% (vol/vol) defatted skim milk before probing with either an anti-phospho-SMAD2 antibody detecting phosphorylation at serine residues 465/467 (1:500, Upstate Biotechnology, Lake Placid, NY, USA), an anti-SMAD2 antibody (1:500, Transduction Laboratories, Franklin Lakes, NJ, USA), a rabbit polyclonal anti-phospho-ERK1/ERK2 antibody (1:500, Promega, Madison, WI, USA), a rabbit polyclonal anti-ERK1/ERK2 antibody (1:1000, Santa Cruz Biotechnology, Santa Cruz, CA, USA), a rabbit polyclonal anti-phospho-STAT5 antibody (1:500, Upstate Biotechnology), or a mouse monoclonal anti-STAT5 antibody (1:500, Transduction Laboratories, Lexington, KY, USA). For detection by enhanced chemiluminescence (Amersham), the blots were incubated with a horseradish peroxidase-conjugated affinity-purified goat anti-rabbit IgG (1:2000, Jackson Immuno Research Laboratories, West Grove, PA, USA) or anti-mouse IgG (1:2500, Dianova, Hamburg, Germany). For reprobing, the blots were stripped by 62.5 mM Tris-HCl pH 8.0, 100 mM ␤-mercaptoethanol, 2% (weight/vol) SDS.
RT-PCR
RT-PCR was performed according to standard techniques as previously described. 24 Briefly, total RNA was prepared from 1 × 10 6 CD34 + cells. Five g of total RNA were transcribed using Super Script (Gibco BRL) according to the manufacturer's instructions. SMAD2 transcripts were amplified (35 cycles) using a Perkin Elmer Cetus DNA thermal cycler (Cetus, Emeryville, CA, USA) in 50 l of PCR buffer containing 100 M Tris-HCl, pH 8.8, 1 M dNTPs, 1 U of Taq polymerase (Amplitag; Cetus), and 2.5 mmol/ml of each primer (SMAD2 forward 5Ј-TAA TAC TAA ATG TGT TAC CAT-3Ј; and SMAD2 reverse 5Ј-ACT GGT GTC TCA ACT CTC TGA T-3Ј). The PCR cycling temperatures were 94°C (1 min) for denaturation, 50°C (1 min) for annealing, and 72°C (1 min) for extension. For normalization of RT-PCR efficiency in the different samples, 30 cycles of ␤-actin RT-PCR were performed using the following primers: ␤-actin forward 5Ј-GTG GGG CGC CCC AGG CAC CA-3Ј, ␤-actin reverse 5Ј-CTC CTT AAT GTC ACG CAC GAT TTC-3Ј. The PCR cycling temperatures were set at 94°C (30 s) for denaturation, 60°C (30 s) for annealing and 72°C (30 s) for extension. PCR samples were visualized on an ethidium bromide stained 1% agarose gel.
Statistical analysis
Data are expressed as mean ± standard deviation (s.d.) and were compared using a paired Student's t-test or as indicated in the results section. P values were calculated to be P Ͻ 0.05 for significant differences.
Results
TGF␤ leads to sustained phosphorylation of SMAD2 in M-07e cells and inhibits TPO-induced thymidine incorporation, proliferation and survival
Megakaryoblastic growth factor-dependent M-07e cells were chosen as a model cell line to study the proliferative responses to TGF␤ and TPO. TPO enhanced thymidine incorporation up to six-fold as early as 36 h after exposure as compared to culture conditions without exogenous cytokines (Figure 1a) , and cell survival and the number of viable cells were increased beginning on day 7 of culture ( Figure 1b, c) . TGF␤ strongly inhibited TPO-induced thymidine incorporation (P Ͻ 0.05), survival, and cell proliferation (Figure 1a-c) . TGF␤ reduced 3 H-thymidine incorporation induced by interleukin-3 (IL-3) to the same extent (Figure 1a) .
We asked whether SMAD2 was expressed and activated by TGF␤ in M-07e cells and another myeloid cell line (HEL). By RT-PCR, SMAD2 transcripts were detected in both cell lines, and Western blot analysis revealed expression of SMAD2 protein (Figure 2a ). Exposure to TGF␤ resulted in phosphorylation of SMAD2 protein which began 10 min after exposure and reached a maximum after 1 h, whereafter SMAD2 remained phosphorylated for at least 19 h (Figure 2c ).
TGF␤-mediated inhibition of TPO-induced thymidine incorporation is enhanced by AG490, but not PD098059 in M-07e cells
Since JAK-STAT and MAPK pathways are activated by TPO and have recently been linked to TGF␤-mediated signaling by the description of crosstalk mechanisms, we asked whether inhibition of the JAK-STAT and MAPK pathways by selective inhibitors (AG490 and PD098059, respectively) revealed a role of these molecules in the response of M-07e cells to TGF␤. TGF␤-mediated inhibition of TPO-induced effects was enhanced by AG490, as demonstrated by a significant additional decrease of thymidine incorporation (P Ͻ 0.05 vs TPO and TGF␤) ( Figure 1a) . As shown in Figure 1a , AG490 also significantly enhanced TGF␤-mediated reduction of IL3-induced thymidine incorporation (P Ͻ 0.05).
Exposure of M-07e cells to PD098059 led to a reduction of TPO-induced thymidine incorporation (P Ͻ 0.05), cell proliferation and survival (Figure 1a-c) . In contrast to AG490, PD098059 did not enhance TGF␤-mediated inhibition of TPO-induced thymidine incorporation or cell growth ( Figure  1a and c) , although TGF␤-mediated reduction of TPOinduced cell survival was weakly enhanced by PD098059 (Figure 1b) . Similar to TPO, inhibition of IL-3 induced thymidine uptake by TGF␤ was not enhanced by PD098059 (Figure 1a ).
PD098059 at a concentration of 20 M selectively inhibited MAPK but not STAT5 activation (Figure 2b ). Since MAPK pathways have been described to mediate some of the TGF␤-induced effects in epithelial cells and given the faster kinetics of MAPK as compared to SMAD2 activation, we were interested in whether TGF␤-induced phosphorylation of SMAD2 was affected by the MAPK inhibitor. However, preincubation with PD098059 did not affect TGF␤-induced SMAD2 phosphorylation nor its expression (Figure 2c ).
Figure 1
Effect of AG490 and PD098059 on TGF␤-mediated inhibition of TPO-or IL3-induced 3 H thymidine incorporation, cell viability and cell growth in M-07e cells. (a) Cells were incubated with TPO (100 ng/ml) and/or IL-3 (10 ng/ml) in combination with TGF␤ (100 ng/ml) and AG490 (100 M) or PD098059 (20 M) for 36 h. During the last 12 h, 37 kBq of 3 H thymidine were added per well. Thymidine incorporation is depicted as percentage of control (without exogenous cytokines). Significant differences were calculated using Student's t-test (P Ͻ 0.05) as specified in the Result section.
(b) and (c) Cells were incubated for 9 days with TPO (filled squares), TPO and PD098059 (open squares), TPO and TGF␤ (filled triangles), TPO + TGF␤ + PD098059 (open triangles) at the above-mentioned concentrations, or without cytokines (filled circles). An aliquot was analyzed at the indicated times for viability (trypan exclusion) and cell growth (cell counting).
TGF␤ induces phosphorylation of SMAD2 and inhibits TPO-induced thymidine incorporation, survival, and proliferation in CD34 + cells from normal donors
In CD34 + cells from normal bone marrow, we could confirm many of the effects seen in M-07e cells. Having established dose relationships and time kinetics for TGF␤ in M-07e cells, we used saturating amounts of TGF␤ (100 ng/ml) for all experiments and 60 min of TGF␤ preincubation for Western blot analyses. TPO-induced thymidine incorporation ( Figure  3b ), as well as survival and cell proliferation (not shown) were inhibited by TGF␤. Interestingly, TGF␤ led to a consistent decrease of thymidine incorporation in CD34 + cells even under unstimulated conditions (P Ͻ 0.05) (Figure 3a ). We were able to demonstrate transcripts of SMAD2 by RT-PCR in all normal CD34 + cell samples examined (Figure 2a) , and Western blot analysis revealed the expression of SMAD2 protein (Figure 2d ). TGF␤ resulted in phosphorylation of SMAD2 in all samples tested (Figure 2d) .
AG490 was able to inhibit TPO-induced thymidine incorporation in normal CD34
+ cells (NP2 and NP3 in Figure 4 ). AG490 significantly enhanced TGF␤-mediated inhibition of TPO-induced thymidine incorporation after 36 h (P Ͻ 0.05).
Compared with AG490, PD098059 led to a weaker reduction of TPO-induced thymidine incorporation (Figure 4 ). PD098059 did not enhance TGF␤-mediated inhibition of TPO-induced thymidine incorporation in normal CD34
+ cells (Figure 4) .
The stimulatory effect of TGF␤ in a subset of AML reverts to growth inhibition in the presence of TPO
Cells from patients with AML have been shown to differ biologically from their normal counterparts in their response to positive and negative growth factors. We therefore studied the Leukemia responses of bone marrow-derived CD34 + cells which are known to be highly enriched in leukemic stem cells. Bone marrow-derived CD34 + leukemic blasts from patients with AML after MDS were found to show two types of growth responses to TGF␤ (Figure 3a) : while growth inhibition was observed in four of seven samples (cases AML4, AML5, AML6, AML7 from Table 1 ), exposure to TGF␤ stimulated proliferation in the other three of seven samples (cases AML1, AML2, AML3) (P Ͻ 0.05 vs normal samples). In the presence of TGF␤, TPO reverted TGF␤-mediated stimulation of thymidine incorporation to inhibition (P = 0.39 vs normal samples) (Figure 3b ).
We were interested in whether the altered TGF␤ response of the three leukemic samples (AML1-3) was associated with defective signal transduction in these cells. SMAD2 transcripts were detected in all samples (Figure 2a , with the band in AML6 being barely visible), and Western blot analysis revealed that SMAD2 protein was expressed in all samples (Figure 2d) . TGF␤ led to phosphorylation of SMAD2 in all CD34
+ cell samples tested, regardless of their proliferative response to TGF␤ alone (Figure 2d) .
One of the patients whose cells were stimulated by TGF␤ alone (AML3) was investigated further for a possible role of JAK-STAT and MAPK molecules. In CD34 + cells from this patient, AG490 significantly enhanced TGF␤-mediated inhibition of TPO-induced thymidine incorporation (P Ͻ 0.05) (AML3 in Figure 4 ). Interestingly and differently from normal CD34 + cells, PD098059 was also able to enhance TGF␤-mediated decreases of TPO-induced thymidine incorporation in this patient (P Ͻ 0.05) (Figure 4 ).
Discussion
These data provide evidence that TGF␤ fails to inhibit thymidine incorporation in CD34
+ cells from a subset of patients with + cells from normal bone marrow and CD34 + leukemic blasts from patients with MDS-derived AML. ␤-Actin RT-PCR was used to normalize the amount of RNA that was used for amplification. (b) Western blot analysis of PD098059 effects on the phosphorylation of MAP kinases Erk1 and Erk2 and on STAT5. M-07e cells were incubated for 10 min with thrombopoietin (100 ng/ml) with or without preincubation with 20 M PD098059 for 4 h. Anti-phosphoErk and anti-phosphoSTAT5 antibodies were used to detect active Erk and active STAT5, respectively, and anti-Erk and anti-STAT5 antibodies were used to demonstrate equal expression and loading of the proteins. (c) Western blot analysis of SMAD2 expression and TGF␤-induced SMAD2 phosphorylation. M-07e and HEL cells were exposed to TGF␤ (100 ng/ml) with or without 20 M PD098059, or TPO (100 ng/ml), or TGF␤ and TPO for 1 h (left and middle panel). For kinetic studies, HEL cells were stimulated with TGF␤ for the indicated times and analyzed for phosphorylation of SMAD2 (right panel). (d) Western blot analysis of SMAD2 expression and TGF␤-induced SMAD2 phosphorylation in CD34 + cells from the bone marrow of four patients with MDS-derived AML (right panel) as compared to three healthy donors (left panel). For analysis of SMAD2 expression and SMAD2 phosphorylation, cells were incubated without or with TGF␤ (100 ng/ml) for 1 h. A control antibody (anti-SMAD2) was used to verify equal expression of the proteins.
MDS-derived AML. This was not due to a loss of SMAD2 gene expression or abrogated phosphorylation of SMAD2 protein and suggests signaling defects downstream of SMAD2 in these cells. In myeloid cell lines, TGF␤ led to sustained phosphorylation of SMAD2 with maximal phosphorylation achieved 60 min after stimulation. It was asked whether activation of SMAD2 could be demonstrated in the CD34 + cell fraction of normal bone marrow which is highly enriched in hematopoietic stem cells. SMAD5 has been demonstrated to contribute to TGF␤-induced growth arrest in normal CD34
+ cells, 25 and addition of SMAD5 antisense oligonucleotides led to abrogation of this growth arrest. However, expression and phosphorylation of SMAD5 protein were not evaluated. Here, the expression of SMAD2 mRNA and protein, as well as phosphorylation of SMAD2 protein is demonstrated in CD34 + cells. These cells were growth-inhibited by TGF␤ as shown by 3 Hthymidine uptake assays as early as 36 h after stimulation.
Due to insufficient yields of total protein from bone marrowderived CD34
+ cells, CD34 + cells from mobilized peripheral blood, which have been described to be growth-inhibited TGF␤, 26 were used for Western blot analysis. Although not formally proven by inhibition of SMAD2 function, these results point to a role of SMAD2 in TGF␤-mediated effects in normal CD34
+ cells. CD34
+ cells from three of seven patients with AML after MDS failed to show inhibition of thymidine incorporation by TGF␤. Loss of sensitivity to TGF␤-induced growth arrest has been described in clonogenic cells from patients with MDSderived AML, 17 and this was, in part, attributed to decreased TGF␤ binding sites on the surface of these cells. However, the authors did not study phosphorylation of SMAD2 or any other TGF␤ signaling molecules. The number of TGF␤ receptors in CD34
+ cells from patients with MDS-derived AML is not known, but the fact that TGF␤ leads to strong phosphorylation + cells from normal donors and from patients with AML after MDS. Cells were incubated with TGF␤ (100 ng/ml) as described in Materials and methods, and fold 3 H thymidine uptake was calculated as compared with 3 H thymidine incorporation in the absence of exogenous cytokines. (b) Proliferative response to either TPO (100 ng/ml) (white bars), TGF␤ (100 ng/ml) (black bars), or TPO and TGF␤ (100 ng/ml each) (grey bars), of highly purified bone marrow-derived CD34 + cells from healthy donors (n = 4) and patients with AML after MDS as detected by a Effects of AG490 and PD098059 on TGF␤-mediated inhibition of TPO-induced thymidine incorporation (% of control) as detected in bone marrow-derived CD34 + cells from two normal subjects (NP2 and NP3) and one patient with AML after MDS (AML3). CD34 + cells were incubated with TPO (dotted bars), TPO + AG490 (coarse network), TPO + PD098059 (fine network), TPO and TGF␤ (black), TPO + TGF␤ + AG490 (light grey), or TPO + TGF␤ + PD098059 (dark grey). Reduction of thymidine incorporation by AG490 in the presence of TGF␤ and TPO was significant in all cases (P Ͻ 0.05 by t-test) while reduction by PD098059 was significant only in AML3 (P Ͻ 0.05 by t-test).
of SMAD2 in CD34
+ cells from patients with AML after MDS suggests that a decrease in TGF␤ receptors may not be a major contributing factor to defective growth arrest in these cells.
Since SMAD2 was expressed and phosphorylated in CD34 + cells from patients with AML after MDS regardless of their response to TGF␤, signaling defects downstream of SMAD2 may have been responsible in those cells which did not show decreased thymidine incorporation upon exposure to TGF␤. Several mechanisms of interference with SMAD function have been described, such as inhibition of nuclear translocation of SMAD2, 27 binding of SMAD proteins by oncogenic transcription factors, 28, 29 and upregulation of inhibitory SMAD molecules. 30 Oncogenic ras, acting via MAPK, inhibits TGF␤-mediated signaling by phosphorylation of SMAD2 at sites difLeukemia ferent from TGF␤ receptor-induced phosphorylation, which then suppresses nuclear translocation of SMAD2. 27 Thus, inhibition of MAPK by a selective MEK-1 inhibitor PD098059 31, 32 may lead to enhanced TGF␤ responses. While this was not the case in M-07e cells and normal CD34
+ cells, interestingly, cells from one patient with MDS-derived AML showed enhancement of TGF␤-induced inhibition of TPO-induced thymidine incorporation by addition of PD098059 (Figure 4 ). This may argue for a role of MAPK in the regulation of proliferative responses to TGF␤ in AML after MDS. Two oncogenic transcription factors, Evi-1 and Ski, have recently been described to inhibit TGF␤-induced growth arrest in myeloid cells by interference with activated SMAD proteins and prevention of binding to DNA target sequences. 28, 29 Evi-1 has been reported to be overexpressed in secondary AML, and the t(3;21) translocation found in secondary AML and CML blast crisis has been demonstrated to result in generation of an AML1-Evi1 fusion protein. This fusion protein has transforming potential and is able to induce acute myeloid leukemia in mice. 33 However, in the three patients of our study that failed to respond to TGF␤ alone, no t(3;21) was detected (Table 1) . Since interferon gamma-induced activation of the JAK-STAT signal transduction pathway has also been described to inhibit TGF␤-mediated signaling, 30 it was analyzed whether inhibition of TPO-induced JAK-STAT activation by a specific JAK2 inhibitor (AG490) 34 enhanced the effects of TGF␤. In fact, we found enhancement of TGF␤-mediated inhibition of TPO-induced effects in all cells analyzed, including M-07e cells and CD34
+ cells from normal donors and patients with AML after MDS. The effects of TGF␤ were not specific for TPO as was confirmed by the use of IL-3 ( Figure  1a ). These data support antagonistic regulation of TGF␤ by JAK-STAT molecules in myeloid progenitor cells. The mechanism postulated by Ulloa et al 30 includes induction of SMAD7 which acts by inhibiting the recruitment and phosphorylation of SMAD2 and SMAD3 to TGF␤ receptors, but SMAD2 was phosphorylated in CD34 + cells from all examined patients with AML after MDS (Figure 2d ). Nevertheless, antagonistic JAK-STAT molecules may play a role in TGF␤ resistance as CD34
+ cells that were unresponsive to TGF␤ alone showed a higher thymidine uptake in the presence of TPO as compared to CD34
+ cells which were responsive to TGF␤ alone ( Figure 3) .
In summary, our data support the hypothesis that CD34 + leukemic progenitor cells from patients with AML after MDS display altered TGF␤ signal transduction pathways which may allow these cells to escape from TGF␤-mediated growth control and gain a survival advantage over their normal counterparts.
